NASDAQ$RNA

Atrium Therapeutics Inc · Q3 2022 earnings

Q3 2022 earnings ·

Headline financials

Total Revenue

$2.48M

Previous: $2.16M+14.7%
EPS

-$0.82

No prior period
Capital Expenditures

-$1.97M

Previous: -$2.03M+3.0%
Free Cash Flow

-$45.6M

Previous: -$31.3M-45.6%
Net Income

-$43.6M

Previous: -$29.3M-48.9%
Operating Income

-$44.9M

Previous: -$29.3M-53.4%
Gross Profit

$0.00

Previous: $0.00

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$2.48M

Q3 2022+14.7%vs Q3 2021
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro